3 days popular7 days popular1 month popular3 months popular

Breast cancer patients 60+ with luminal A subtype may not need radiation if on hormone therapy

Women with luminal A subtype breast cancer – and particularly those older than 60 – may not need radiation treatment if they are already taking hormone therapy, shows clinical research led by radiation oncologists at the Princess Margaret Cancer Centre published online in the Journal of Clinical Oncology. The findings potentially advance delivery of personalized [...]

Hormones with statins may help women’s hearts after menopause

Hormones may not protect women from heart disease or stroke after menopause, but when combined with cholesterol-lowering statin drugs, they may help protect women from these killers, shows a population study from Sweden to be published in the April issue of Menopause, the journal of The North American Menopause Society (NAMS). During the study, women [...]

Hormone Replacement Therapy for postmenopausal women: Does it help or harm your heart?

New evidence published in the Cochrane Library shows that hormone replacement therapy does not protect post-menopausal women against cardiovascular disease, and may even cause an increased risk of stroke. HRT, now more commonly known as hormone therapy, is widely used for controlling menopausal symptoms. It has also been used for the prevention of cardiovascular disease [...]

Study finds hormone therapy in transgender adults safe

In the most comprehensive review to date addressing the relative safety of hormone therapy for transgender persons, researchers from Boston University School of Medicine (BUSM) have found that hormone therapy in transgender adults is safe. The findings, which appear in the Journal of Clinical and Translational Endocrinology, may help reduce the barriers for transgender individuals [...]

Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis. The [...]